Nephrotoxicity following administration of methoxyflurane has been shown to be directly related to anesthetic metabolism to inorganic fluoride. Enzyme induction should increase metabolic rate and the amount of inorganic fluoride that is released. In vivo studies in Fischer 344 rats show that enzyme induction with phenobarbital or phenytoin increases defluorination following methoxyflurane anesthesia but not after enflurane or isoflurane. In vitro, methoxyflurane defluorinase activity was increased far more than that of any of the other anesthetics. These data suggest that treatment with enzyme inducing drugs increases the risk of nephrotoxicity only if methoxyflurane is the anesthetic agent.
For purposes of this discussion, the potent, fluorinated, inhalational anesthetics are considered halothane-related compounds. They differ from halothane in that they are aliphatic ethers which when biotransformed liberate inorganic fluoride. Halothane is a fluorinated ethane which, except under conditions of extreme hypoxia, does not breakdown to inorganic fluoride (1) . Since postanesthetic nephrotoxicity is directly related to inorganic fluoride concentration in the serum, halothane should not be considered a nephrotoxin.
Nephrotoxicity associated with anesthetic administration was first reported by Crandell et al. (2) in a study of patients anesthetized with methoxyflurane (CHC12-CF2-0-CH). Thirteen of 41 patients had polyuria with negative fluid balance, increased serum sodium and blood urea nitrogen concentrations and fixed urinary osmolality, close to that of serum. Polyuria was resistant to fluid deprivation and vasopressin administration. These findings were later confirmed in both man and animals (3, 4) . Besides methoxyflurane, only enflurane (CHClF-CF2-0-CF2H) administration has resulted in decreased urinary concentrating ability. (11) .
There was no difference in concentrating ability in this study among patients anesthetized with enflurane and with halothane, the control anesthetic agent. However volunteers anesthetized with enflurane for 9.6 MAC-hr had mean peak inorganic fluoride levels of 34 gM. They had a 26% decrease in preanesthetic concentrating ability during the first 24 hr following anesthesia (12) . This impairment was transient and probably would be clinically insignificant in patients with normal preanesthetic renal function.
Figure I correlates peak serum inorganic fluoride level following halothane, enflurane, and methoxyflurane anesthesia with decreased urinary osmolality as measured by the response to vasopressin administration; data are from the studies referred to above. The positive correlation between impaired urinary concentrating ability and serum inorganic fluoride level following administration of different anesthetics is strong evidence that anesthetic nephrotoxicity in man is due to metabolic liberation of inorganic fluoride.
Studies employing Fischer 344 rats have provided further evidence relating anesthetic metabolism to nephrotoxicity. Mazze et al. (4) reported vasopressin-resistant polyuric renal insufficiency following either anesthesia with methoxyflurane or injection of inorganic fluoride. Cousins et al. (13) showed that phenobarbital treatment of Fischer 344 rats prior to methoxyflurane anesthesia resulted in higher serum inorganic fluoride levels and more severe nephrotoxicity than in control animals (Fig. 2) . Conversely, administration of SKF 525A, an inhibitor of drug metabolizing enzymes resulted in lower serum inorganic fluoride concentrations and less nephrotoxicity (Fig. 3) . They also showed that inorganic fluoride was the principal nephrotoxic metabolite rather than oxalic acid, the organic end product of methoxyflurane metabolism. Oxalic acid administration resulted in nephrotoxicity only when injected in quantities 10-fold greater than the amount excreted following a nephrotoxic exposure to methoxyflurane; at that, oxalic acid induced nephrotoxicity was of an oliguric rather than a polyuric nature (Fig. 4) 
Effect of Other Inducing Agents
Most research on the induction of enzymes which defluorinate the volatile anesthetics has been performed using phenobarbital as the inducing agent.
The rationale for this method of procedure has been that all volatile anesthetics belong to the same class of substrates and, presumably, are metabolized by the same enzyme (17) . If this were correct, induction of defluorination of different anesthetics by phenobarbital should have been uniform. Data in Table I indicate that this is not the case. Therefore, we have begun to examine the effects of other inducing agents on the defluorination of the volatile anesthetics. Preliminary data suggest that 3-methylcholanthrene has no effect on methoxyflurane metabolism and nephrotoxicity, whereas phenytoin was found to have nearly the same effect as phenobarbital, both in vivo and in vitro (18) .
Effect of Enzyme-inducing Agents on Anesthetic Nephrotoxicity in Humans
There are no data in humans relating drug treatment and anesthetic defluorination. However, studies of anesthetic metabolism have demonstrated large variations in the amount of defluorination among individuals which could be due to enzyme induction (3, (8) (9) (10) (11) (12) . In one study, Cousins et al. (11) reported a patient with a peak serum inorganic fluoride concentration of 106 ,uM following enflurane anesthesia, considerably greater than the mean volume of 22 AM measured in the remaining patients. This patient was on a multiple drug treatment program and it was felt that his enzymes may have been induced. These suggestions of enzyme induction in surgical patients clearly indicate the need for further clinical investigations. At the present time, however, we can only speculate as to the effects of treatment with enzyme inducing drugs on the metabolism and nephropathy of the fluorinated anesthetics. Based on animal data, we would predict the following: methoxyflurane should be more nephrotoxic in enzyme-induced patients; it is unlikely that enflurane metabolism can be significantly induced so that its nephrotoxicity should be unrelated to drug treatment history; isoflurane and sevoflurane metabolism may be increased by enzyme induction, however, inorganic fluoride levels still should be well below the nephrotoxic threshold of 35-50 ,uM; and halothane defluorination ordinarily should not be increased by enzyme induction, so that it will not be nephrotoxic in clinical practice.
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